CDT Equity (NASDAQ:CDT) Shares Down 3.3% – Time to Sell?

by · The Markets Daily

CDT Equity Inc. (NASDAQ:CDT – Get Free Report)’s stock price dropped 3.3% on Friday . The stock traded as low as $1.73 and last traded at $1.75. Approximately 77,224 shares traded hands during trading, a decline of 83% from the average daily volume of 451,466 shares. The stock had previously closed at $1.81.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of CDT Equity in a research note on Monday, December 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Stock Report on CDT Equity

CDT Equity Trading Down 3.3%

The firm has a market capitalization of $2.85 million, a PE ratio of 0.00 and a beta of 1.78. The firm has a 50 day simple moving average of $2.78 and a 200 day simple moving average of $10.62.

CDT Equity (NASDAQ:CDT – Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($13.16) earnings per share (EPS) for the quarter.

Institutional Trading of CDT Equity

A hedge fund recently bought a new stake in CDT Equity stock. Apollon Wealth Management LLC acquired a new stake in shares of CDT Equity Inc. (NASDAQ:CDT – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned about 28.28% of CDT Equity as of its most recent SEC filing. 3.29% of the stock is currently owned by institutional investors.

About CDT Equity

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Featured Articles